12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MM-121: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 28 patients with platinum-resistant gynecological cancers or HER2 non-overexpressing breast cancer showed that MM-121 plus paclitaxel produced a CBR of 70%. Specifically, 48% of patients achieved a partial response and of those, 39% achieved a confirmed...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >